PHG Stock Overview
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pharming Group N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.30 |
| 52 Week High | €12.50 |
| 52 Week Low | €8.80 |
| Beta | 0.73 |
| 1 Month Change | -7.92% |
| 3 Month Change | -15.45% |
| 1 Year Change | -3.63% |
| 3 Year Change | -9.71% |
| 5 Year Change | n/a |
| Change since IPO | -18.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.6% | -4.3% | -2.5% |
| 1Y | -3.6% | -19.4% | -0.4% |
Return vs Industry: PHG exceeded the German Biotechs industry which returned -15.8% over the past year.
Return vs Market: PHG underperformed the German Market which returned 1% over the past year.
Price Volatility
| PHG volatility | |
|---|---|
| PHG Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PHG's share price has been volatile over the past 3 months.
Volatility Over Time: PHG's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 382 | Simon de Vries | www.pharming.com |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Pharming Group N.V. Fundamentals Summary
| PHG fundamental statistics | |
|---|---|
| Market cap | €646.84m |
| Earnings (TTM) | -€9.89m |
| Revenue (TTM) | €229.91m |
2.8x
P/S Ratio-65.4x
P/E RatioIs PHG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHG income statement (TTM) | |
|---|---|
| Revenue | US$245.32m |
| Cost of Revenue | US$25.21m |
| Gross Profit | US$220.10m |
| Other Expenses | US$230.65m |
| Earnings | -US$10.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -0.016 |
| Gross Margin | 89.72% |
| Net Profit Margin | -4.30% |
| Debt/Equity Ratio | 63.3% |
How did PHG perform over the long term?
See historical performance and comparison